ATE541587T1 - Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen - Google Patents

Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen

Info

Publication number
ATE541587T1
ATE541587T1 AT01941913T AT01941913T ATE541587T1 AT E541587 T1 ATE541587 T1 AT E541587T1 AT 01941913 T AT01941913 T AT 01941913T AT 01941913 T AT01941913 T AT 01941913T AT E541587 T1 ATE541587 T1 AT E541587T1
Authority
AT
Austria
Prior art keywords
addition reactions
controlled release
active substances
pharmaceutically active
conjugate addition
Prior art date
Application number
AT01941913T
Other languages
English (en)
Inventor
Jeffrey Hubbel
Donald Elbert
Ronald Schoenmakers
Original Assignee
Eidgenoess Tech Hochschule
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/586,937 external-priority patent/US6958212B1/en
Application filed by Eidgenoess Tech Hochschule, Univ Zuerich filed Critical Eidgenoess Tech Hochschule
Application granted granted Critical
Publication of ATE541587T1 publication Critical patent/ATE541587T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01941913T 2000-06-02 2001-06-04 Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen ATE541587T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/586,937 US6958212B1 (en) 1999-02-01 2000-06-02 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
PCT/US2001/018101 WO2001092584A1 (en) 2000-06-02 2001-06-04 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds

Publications (1)

Publication Number Publication Date
ATE541587T1 true ATE541587T1 (de) 2012-02-15

Family

ID=24347696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01941913T ATE541587T1 (de) 2000-06-02 2001-06-04 Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen

Country Status (8)

Country Link
EP (1) EP1292709B1 (de)
JP (1) JP2003535066A (de)
AT (1) ATE541587T1 (de)
AU (2) AU7522601A (de)
CA (1) CA2410526C (de)
ES (1) ES2386258T3 (de)
MX (1) MXPA02011891A (de)
WO (1) WO2001092584A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
WO2002055185A2 (en) 2000-10-19 2002-07-18 Eidgenoess Tech Hochschule Block copolymers for multifunctional self-assembled systems
KR101054023B1 (ko) * 2001-11-07 2011-08-04 아이드게노시셰 테크시셰 호흐쉘 취리히 세포 내증식 및 조직 재생을 제어하기 위한 합성 매트릭스
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
EP1471887B1 (de) 2002-02-04 2010-04-21 Elan Pharma International Ltd. Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator
US20040052761A1 (en) * 2002-07-19 2004-03-18 Brent Vernon Localized delivery system for cancer drugs, phenstatin, using N-isopropylacrylamide
AU2003280592B2 (en) * 2002-10-31 2008-12-18 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins
EP1581260B1 (de) 2002-12-31 2014-09-17 Nektar Therapeutics Polymerreagentien mit einer keto- oder verwandten funktion
ATE531447T1 (de) 2003-01-17 2011-11-15 Cornell Res Foundation Inc Injizierbare hydrogel-microsphären aus wässrigem zwei-phasen-system
US7803178B2 (en) 2004-01-30 2010-09-28 Trivascular, Inc. Inflatable porous implants and methods for drug delivery
US7282584B2 (en) 2004-06-16 2007-10-16 Straumann Holding Ag Methylene blue
EP1764404B1 (de) 2005-09-16 2009-11-04 Straumann Holding AG Verwendung von Methylenblau als Polymerisationsinhibitor
DE602004011660T2 (de) 2004-06-16 2009-01-29 Straumann Holding Ag Abdeckmembran
JP4820758B2 (ja) 2004-09-22 2011-11-24 日本化薬株式会社 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤
AU2005308920B2 (en) 2004-11-29 2010-04-15 Dsm Ip Assets B.V. Method for reducing the amount of migrateables of polymer coatings
SE0403014D0 (sv) * 2004-12-10 2004-12-10 Straumann Holding Ag New protein formulation
EP1830863A2 (de) * 2004-12-10 2007-09-12 Straumann Holding AG Proteinformulierung
WO2007008300A2 (en) 2005-05-31 2007-01-18 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Triblock copolymers for cytoplasmic delivery of gene-based drugs
US20070237821A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Nanogel-based contrast agents for optical molecular imaging
JP2009513627A (ja) * 2005-10-27 2009-04-02 ペプトロン カンパニー リミテッド 生理活性物質−血液蛋白質複合体及びこれを利用する生理活性物質の安定化方法
EP1957130B1 (de) 2005-12-09 2010-09-15 DSM IP Assets B.V. Hydrophiler überzug mit einem polyelektrolyten
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
RU2447095C2 (ru) 2006-05-18 2012-04-10 Ниппон Каяку Кабусики Кайся Высокомолекулярный конъюгат подофиллотоксинов
JP5552690B2 (ja) * 2006-09-13 2014-07-16 ディーエスエム アイピー アセッツ ビー．ブイ． 被覆された医療装置
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
JP5548365B2 (ja) 2006-11-08 2014-07-16 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
JP5587612B2 (ja) 2007-02-28 2014-09-10 ディーエスエム アイピー アセッツ ビー．ブイ． 親水性コーティング
CN101622020B (zh) 2007-02-28 2015-07-01 帝斯曼知识产权资产管理有限公司 亲水性涂层
JP5349318B2 (ja) 2007-09-28 2013-11-20 日本化薬株式会社 ステロイド類の高分子結合体
CN101977631A (zh) 2008-03-18 2011-02-16 日本化药株式会社 生理活性物质的高分子量偶联物
JP5366940B2 (ja) 2008-05-08 2013-12-11 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
US9271929B2 (en) 2008-11-25 2016-03-01 École Polytechnique Fédérale De Lausanne (Epfl) Block copolymers and uses thereof
JP5544357B2 (ja) 2009-05-15 2014-07-09 日本化薬株式会社 水酸基を有する生理活性物質の高分子結合体
EP2566334B1 (de) * 2010-05-05 2018-04-18 Prolynx, LLC Gesteuerte wirkstofffreisetzung aus festen trägern
JP5907957B2 (ja) 2010-06-16 2016-04-26 ディーエスエム アイピー アセッツ ビー．ブイ． 親水性コーティングを製造するためのコーティング配合物
US20130157926A1 (en) * 2010-06-18 2013-06-20 Johannes Franciscus Joseph Engbersen Boronated polymers
KR20140024833A (ko) 2010-11-17 2014-03-03 니폰 가야꾸 가부시끼가이샤 신규한 시티딘계 대사길항제의 고분자 유도체
CN103874722B (zh) 2011-09-11 2016-06-29 日本化药株式会社 嵌段共聚物的制造方法
EP2826492A4 (de) * 2012-03-13 2015-10-21 Postech Acad Ind Found Arzneimittelabgabekonjugat mit kontrollierter freisetzung und verwendung davon
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
CN113278094B (zh) * 2021-05-31 2022-03-01 兰州大学 一种环糊精衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
WO1998032466A1 (en) * 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
US6372205B1 (en) * 1997-06-11 2002-04-16 The School Of Pharmacy, University Of London Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs
US5945457A (en) * 1997-10-01 1999-08-31 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science Process for preparing biologically compatible polymers and their use in medical devices
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK1181323T3 (da) * 1999-02-01 2011-10-17 Eidgenoess Tech Hochschule Biomaterialer dannet med nukleofil additionsreaktion med konjugerede uimættede grupper
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives

Also Published As

Publication number Publication date
EP1292709A4 (de) 2004-09-22
MXPA02011891A (es) 2004-04-02
WO2001092584A1 (en) 2001-12-06
EP1292709A1 (de) 2003-03-19
AU2001275226B2 (en) 2007-06-28
CA2410526C (en) 2012-04-17
ES2386258T3 (es) 2012-08-14
CA2410526A1 (en) 2001-12-06
AU7522601A (en) 2001-12-11
JP2003535066A (ja) 2003-11-25
EP1292709B1 (de) 2012-01-18

Similar Documents

Publication Publication Date Title
ATE541587T1 (de) Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen
DK1181323T3 (da) Biomaterialer dannet med nukleofil additionsreaktion med konjugerede uimættede grupper
ATE407676T1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
BR0115531A (pt) Tratamento de mucosites
ATE429416T1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
BR0107942A (pt) Polìmeros de proteìna de liberação lenta
DE60030124D1 (de) Hyaluronsäure-ester zur behandlung von normotrophischen hautnarben
DE69903351D1 (de) Vernetzte hyaluronsäure und ihre medizinischen verwendungen
AR032293A1 (es) Estuche farmaceutico
BR9508031A (pt) Composto antiviral composição farmacéutica ou veterinária e processo para o tratamento antiviral profilático ou terapéuitco de um humano ou animal náo humano e uso do composto
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
BR0210335A (pt) Copolìmero de blocos, e, composição
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
CY1108377T1 (el) Χρηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια της ακρατειας ουρων
CY1105125T1 (el) Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων
PT1169460E (pt) Preparacao de moleculas biologicamente activas.
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
HN1998000144A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa.
BR0117123A (pt) Dispositivo de retenção gástrica expansìvel
SE0003476D0 (sv) Compounds
DE60015508D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
AR003001A1 (es) Composicion farmaceutica estimuladora de la osteogenesis.
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων